Trulicity (Dulaglutide) in Girls Under 12: What Families Need to Know About the Transition to Adult Care

Why Girls Under 12 Are Sometimes Prescribed Dulaglutide

Dulaglutide is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes in adults and, since 2022, in children aged 10 and older. Below age 10, any use is strictly off-label.

Yet pediatric obesity and early-onset type 2 diabetes are rising sharply, particularly in girls. The TODAY study found that type 2 diabetes in youth progresses faster and with more complications than in adults, and that girls in the study lost beta-cell function more rapidly than boys. That sex difference matters clinically: a girl's hormonal environment, even before puberty, shapes how her pancreas and insulin-signaling pathways respond to any intervention.

When pediatric endocrinologists prescribe dulaglutide off-label in girls younger than 10 to 12, they are typically managing one of three situations:

• Severe obesity with metabolic consequences (elevated fasting glucose, dyslipidemia, early insulin resistance)
• Early-onset type 2 diabetes not controlled by metformin alone
• Rare genetic syndromes with severe hyperinsulinism or hyperphagia, such as Prader-Willi syndrome

Whatever the indication, the prescribing family needs a clear picture of where the drug came from, where it is going, and how a girl's biology will change that trajectory.

What the FDA Label Actually Covers (and What It Does Not)

The FDA-approved prescribing information for Trulicity states approval for glycemic control in adults with type 2 diabetes and for cardiovascular risk reduction in adults with established cardiovascular disease or multiple risk factors. The 2022 supplemental approval extended use to pediatric patients aged 10 years and older with type 2 diabetes.

Children younger than 10 are not included. There are no randomized controlled trial data for dulaglutide in girls under age 10, and the AWARD-PEDS trial, which supported the 2022 pediatric label, enrolled participants aged 10 to 17. AWARD-PEDS showed that dulaglutide 1.5 mg once weekly reduced HbA1c by approximately 0.6 percentage points more than placebo at 26 weeks in this age group.

Extrapolating those findings to younger children, and especially to girls whose bodies are pre-pubertal, requires clinical judgment and should happen only inside a specialized pediatric endocrinology setting with frequent monitoring.

What "Off-Label" Means for Your Daughter

Off-label prescribing is legal and common in pediatrics; roughly 75% of drugs prescribed to hospitalized children are used outside their licensed indications. Off-label does not mean unsafe. It does mean that the evidence base is thinner, that dosing is extrapolated from older or adult populations, and that the prescribing clinician carries a heightened duty to document rationale and obtain informed consent.

For a girl under 12, informed consent involves the parent or guardian and, where the child is developmentally able, assent from the child herself.

Sex-Specific Physiology: Why Being a Girl Changes Everything

This section is not optional background. The female hormonal environment fundamentally alters how dulaglutide works, what side effects look like, and what monitoring is needed.

Puberty and Insulin Resistance

Puberty in girls causes a transient but significant increase in insulin resistance, driven by rising estrogen, growth hormone pulsatility, and adrenal androgen secretion. Studies using hyperinsulinemic-euglycemic clamps show that insulin sensitivity drops by approximately 30% during mid-puberty before partially recovering in late puberty. This means that a dose of dulaglutide that was adequate at Tanner stage 1 may need adjustment by Tanner stage 3.

GLP-1 receptors are expressed in the ovary, uterus, and hypothalamic-pituitary axis. Animal data suggest GLP-1 agonism may modulate gonadotropin release, though clinical significance in human girls is still being studied. Clinicians should document menstrual onset (menarche) and cycle regularity as baseline variables once a girl starts dulaglutide.

The Menstrual Cycle Once It Begins

Once menarche arrives, typically between ages 9 and 15 in girls with obesity (who often experience earlier puberty), the menstrual cycle creates fluctuating estrogen and progesterone levels that influence gastric emptying, appetite, and nausea thresholds. Dulaglutide's most common side effects, nausea and vomiting, may be worse in the luteal phase when progesterone slows gastric motility. Families should track nausea relative to cycle phase; if it is predictably luteal-phase-worse, dose timing adjustments or antiemetic support during that window may help.

Irregular cycles in girls with obesity or early-onset type 2 diabetes often signal underlying polycystic ovary syndrome (PCOS). PCOS affects an estimated 8-13% of women of reproductive age, but the prevalence among adolescent girls with obesity and insulin resistance is substantially higher. GLP-1 agonists have shown promise in PCOS management by improving insulin sensitivity and reducing androgen levels, though most data come from adult women. The presence of irregular cycles, acne, or hirsutism in a girl on dulaglutide should trigger evaluation for PCOS, not just dose adjustment.

Body Composition Differences in Girls

Girls and boys lose weight differently on GLP-1 agonists. Girls carry a higher proportion of subcutaneous fat and a lower proportion of visceral fat than boys of the same BMI. GLP-1-mediated weight loss preferentially reduces visceral fat, which is metabolically beneficial but means girls may see smaller scale changes relative to their metabolic improvements. Clinicians and families should not judge response by weight alone; waist circumference, fasting insulin, and lipid panels matter too.

Dosing in Girls Under 12: What Is Known

The standard starting dose for adults and for children aged 10 and older is 0.75 mg dulaglutide once weekly, with possible uptitration to 1.5 mg weekly after four weeks if tolerated and glycemic response is insufficient.

For girls under 10, no weight-based pediatric dosing algorithm is established in the FDA label. Pediatric endocrinologists who prescribe off-label typically start at 0.75 mg once weekly regardless of weight, given the GI side-effect profile, and uptitrate cautiously. Some academic centers use 0.5 mg compounded formulations for very young or small children, though compounded GLP-1 formulations carry their own quality-control considerations and should only be obtained from 503B outsourcing facilities with USP 797 compliance.

Injection site rotation is important in small bodies with less subcutaneous tissue. Thigh, abdomen, and upper arm sites should be rotated weekly. Injection anxiety is common in young girls; shared decision-making about site selection and use of an autoinjector can meaningfully improve adherence.

Planning the Transition to Adult Care: A Practical Framework

Moving a girl from pediatric endocrinology to adult women's health care is not a single appointment. It is a structured process that should begin at least 12 to 18 months before her 18th birthday, and ideally earlier if her care is complex. Below is the WomanRx framework for dulaglutide-specific transition planning.

Phase 1: Preparation (Ages 14-16, or 2-4 Years Before Transfer)

Start building health literacy early. A girl who understands why she takes dulaglutide, what it does, and what to watch for is far more likely to maintain therapy through the instability of a care transfer.

Key tasks in this phase:

• Confirm that the current pediatric endocrinology team has documented the indication, dosing history, any dose changes tied to puberty, and all prior side effects in a transferable summary.
• Begin transferring prescription management to the patient herself, with supervision. She should be able to draw up (or auto-inject), store, and dispose of the pen correctly.
• Identify adult care providers. Adult endocrinology, obesity medicine, or a women's health specialist with GLP-1 experience should be named by this point.
• Screen for PCOS. An adolescent girl with type 2 diabetes and obesity who has irregular cycles, acne, or excess hair growth should have a formal PCOS evaluation before transfer. PCOS management in adult care may require dulaglutide dose adjustment alongside hormonal contraception.

Phase 2: Transfer Preparation (Age 16-17)

The pediatric team and adult team should overlap. At least one joint visit or shared consultation letter is best practice, per the American Diabetes Association Standards of Care.

Tasks in this phase:

• Contraception counseling is mandatory before transfer (see the Pregnancy and Lactation section below). Dulaglutide is a teratogen in animal models. Any sexually active girl must use reliable contraception.
• Confirm health insurance continuity. Many pediatric-specific insurance plans do not auto-transfer. A gap in dulaglutide coverage can cause rapid glycemic deterioration.
• Assess mental health. Disordered eating, body image distress, and depression are more common in adolescent girls with obesity and diabetes than in the general population. Research in JAMA Pediatrics found that nearly 30% of adolescents with obesity had clinically significant depressive symptoms. A mental health screen at transfer is not optional.
• Review bone health. GLP-1 agonists may modestly reduce bone mineral density in some adult populations; the data in adolescents are sparse. Given that peak bone mass is accrued through the late teens and early twenties, a baseline DXA in girls with prolonged dulaglutide use plus low calcium or vitamin D intake is reasonable.

Phase 3: Active Transfer (Age 17-18)

The first adult appointment should happen before the last pediatric appointment, not after. Overlap eliminates the clinical gap that causes the most harm.

The adult women's health or endocrinology provider should receive:

1. Complete medication history including all dose changes and reasons for each
2. Most recent HbA1c, fasting glucose, lipid panel, and kidney function (eGFR and urine albumin-to-creatinine ratio)
3. Menstrual history: age at menarche, cycle regularity, any PCOS diagnosis or evaluation
4. Growth and pubertal history (Tanner staging documentation)
5. Any imaging (hepatic ultrasound for fatty liver, DXA if performed)
6. Mental health history and current status
7. Family history update, especially maternal history of gestational diabetes, PCOS, or early cardiovascular disease

Pregnancy, Lactation, and Contraception: What Every Girl and Family Must Know

This section applies as soon as a girl on dulaglutide becomes or could become sexually active.

Pregnancy: Dulaglutide Is Contraindicated

Dulaglutide carries FDA Pregnancy Category language indicating that animal reproduction studies showed adverse effects at clinically relevant exposures, including fetal growth restriction and skeletal malformations. Human pregnancy data are very limited. The FDA label states that dulaglutide should be discontinued at least two months before a planned pregnancy, given its half-life of approximately five days but the desire for a substantial washout period before conception.

If a girl on dulaglutide discovers she is pregnant, the drug should be stopped immediately and she should be referred urgently to an OB-GYN or maternal-fetal medicine specialist familiar with diabetes in pregnancy. Her glycemic management will need to transition to insulin, which remains the safest pharmacological option for blood sugar control in pregnancy.

Lactation: Data Are Absent

There are no human data on dulaglutide transfer into breast milk. The molecular weight of approximately 59,669 daltons suggests limited transfer, but GLP-1 receptors are present in breast tissue and the long-term effect on an infant's developing metabolic system is unknown. The Academy of Breastfeeding Medicine advises caution with GLP-1 agonists during lactation until more data exist. A young woman who wishes to breastfeed should discuss with her provider whether to hold dulaglutide during that period and manage diabetes by other means.

Contraception Requirements

Any girl on dulaglutide who is sexually active must use reliable contraception. Dulaglutide slows gastric emptying, which may reduce the absorption of oral contraceptive pills taken during peak nausea periods. A clinician should confirm oral contraceptive pharmacokinetics are not substantially affected, or alternatively recommend a non-oral method such as a levonorgestrel IUD, etonogestrel implant, or depot medroxyprogesterone acetate injection. These methods also offer non-contraceptive benefits relevant to girls with PCOS or heavy menstrual bleeding.

The ACOG Practice Bulletin on Adolescent Contraception recommends that long-acting reversible contraception (LARC) be offered as first-line options for adolescents who need reliable pregnancy prevention, and that discussion of contraception not be contingent on a teen already being sexually active.

Conditions That Dulaglutide May Help in Girls and Young Women

Type 2 Diabetes

This is the on-label indication for ages 10 and older and the most common reason dulaglutide appears in a girl's chart before 12. In AWARD-PEDS, dulaglutide 1.5 mg reduced HbA1c by a mean of 0.57 percentage points versus placebo at 26 weeks, with weight stabilization compared to weight gain in the placebo arm.

PCOS and Insulin Resistance

PCOS is diagnosed in adult women using the Rotterdam criteria (two of three: oligo-ovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound). In adolescents, diagnosis requires all three features given the normal irregularity of early cycles. GLP-1 agonists improve the insulin-resistance component of PCOS and have been shown in adult women to reduce free androgen index and improve cycle regularity. A 2022 meta-analysis in Fertility and Sterility found that GLP-1 agonists reduced free testosterone by a mean of 1.2 nmol/L and improved menstrual regularity in women with PCOS and obesity. These data are from adults; the adolescent evidence base is not yet sufficient to make firm recommendations, but the mechanism is sound.

Obesity and Metabolic Syndrome

The SCALE Obesity and Prediabetes trial in adults (liraglutide, a related GLP-1 agonist) showed a mean weight loss of 8% over 56 weeks. Dulaglutide produces more modest weight loss than semaglutide but remains meaningful in the context of comprehensive obesity management. For a girl whose obesity is driving her early-onset diabetes, dulaglutide is part of a multidisciplinary plan that includes nutrition, physical activity, and behavioral support.

Non-Alcoholic Fatty Liver Disease (NAFLD)

Girls with obesity and type 2 diabetes have high rates of NAFLD, which can progress to fibrosis in adolescence. GLP-1 agonists have shown hepatic benefit in adult trials. A baseline liver ultrasound and periodic ALT monitoring are reasonable in this population.

Who This Is Right For, and Who Should Pause

This framing is not a substitution for individual clinical assessment. It is a guide for the conversation.

More likely to benefit:

• A girl aged 10-11 with confirmed type 2 diabetes not controlled on metformin alone, under pediatric endocrinology supervision
• An adolescent girl with obesity, prediabetes, and PCOS-pattern insulin resistance who has not responded to lifestyle intervention alone
• A girl with a family history of early cardiovascular disease or maternal gestational diabetes who is tracking toward significant metabolic risk

Reasons to pause or reconsider:

• Age under 10 without a compelling clinical rationale and specialist oversight
• Active eating disorder: GLP-1-mediated appetite suppression can worsen restrictive eating in girls with anorexia nervosa or atypical anorexia
• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (class contraindication for all GLP-1 agonists)
• Pregnancy or planning pregnancy within two months
• Severe gastrointestinal dysmotility or history of pancreatitis

Monitoring Schedule for Girls Under 12 on Dulaglutide

Pediatric endocrinologists typically use the following schedule, which should transfer with the patient to adult care:

| Parameter | Frequency | |---|---| | HbA1c | Every 3 months | | Fasting glucose and fasting lipid panel | Every 6 months | | eGFR and urine albumin-to-creatinine ratio | Annually | | Liver enzymes (ALT) | Annually | | Menstrual history and cycle regularity | Every visit once menarche | | Blood pressure and heart rate | Every visit | | Height, weight, BMI percentile, waist circumference | Every visit | | Injection site assessment | Every visit | | Mental health screen (PHQ-A) | Every 6 months | | DXA (if prolonged use and low calcium/vitamin D) | Consider at age 15-16 | | Thyroid nodule surveillance (annual neck palpation) | Every visit |

Evidence Gaps Specific to Girls and Young Women

Women, and especially girls, have been systematically under-represented in metabolic and diabetes trials. The AWARD program, which generated most of dulaglutide's evidence base, enrolled predominantly adult men in its earlier phases. AWARD-PEDS enrolled children aged 10 to 17, but sex-disaggregated data from that trial have not been published as a primary analysis. We do not have direct evidence for:

• Optimal dosing in pre-pubertal girls versus post-pubertal girls
• Whether puberty-related insulin resistance requires dulaglutide dose escalation
• Long-term effects of GLP-1 agonism on ovarian function, reproductive outcomes, or timing of menarche
• Whether dulaglutide during mid-puberty affects peak bone mass accrual

These are not reasons to deny a girl a therapy that may meaningfully reduce her risk of diabetes complications. They are reasons to document, monitor, and contribute data through registries when possible.

Dr. Maya Okafor, WomanRx medical reviewer and OB-GYN, notes: "The girls I see transitioning from pediatric to adult care on GLP-1 therapies often arrive without anyone having addressed their menstrual health, their contraceptive needs, or whether their cycle irregularity might signal PCOS. The handoff to adult women's health care is not just about glucose numbers. It is about a whole hormonal environment that pediatric endocrinology teams are not always trained to address and adult endocrinology teams do not always ask about."